|
End-of-day quote
Dhaka S.E.
15/10/2026
|
5-day change | 1st Jan Change | ||
| 145.80 BDT | +0.62% |
|
+0.83% | +42.80% |
| 01/10 | Beximco Pharmaceuticals Reaches Settlement With Bangladeshi Regulator Over Board Restructuring | MT |
| 01/10 | Beximco Pharmaceuticals PLC Announces Iqbal Ahmed to Step Down from Managing Director | CI |
| Market Cap | 65.04B 528M 469M 435M 396M 746M 50.08B 758M 5.23B 2.05B 26.13B 1.98B 1.94B 83.31B | P/E 2026 * |
7.51x | P/E 2027 * | 6.56x |
|---|---|---|---|---|---|
| Enterprise Value | 65.04B 528M 469M 435M 396M 746M 50.08B 758M 5.23B 2.05B 26.13B 1.98B 1.94B 83.31B | EV / Sales 2026 * |
1.19x | EV / Sales 2027 * | 1.06x |
| Free-Float |
85.91% | Yield 2026 * |
4.13% | Yield 2027 * | 4.73% |
| 1 day | +0.62% | ||
| 1 week | +0.83% | ||
| Current month | -1.22% | ||
| 1 month | -1.95% | ||
| 3 months | -4.89% | ||
| 6 months | +23.98% | ||
| Current year | +42.80% |
| 1 week | 141.6 |  | 146.4 |
| 1 month | 138.5 | | 151.1 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 236 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 04/03/2024 |
| Director of Finance/CFO | 63 | 01/01/2003 | |
Mohammad Haque
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 19/06/2009 | |
| Director/Board Member | - | 01/02/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 01/01/1985 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.62% | +0.83% | +31.71% | -0.27% | 528M | |
| +0.43% | +6.59% | +53.41% | +103.85% | 1,120B | |
| +0.90% | -2.25% | +33.02% | +62.23% | 616B | |
| +0.71% | +3.24% | +25.81% | +93.86% | 504B | |
| -0.13% | +5.98% | +32.91% | +50.39% | 367B | |
| +0.52% | +0.24% | +73.92% | +40.15% | 360B | |
| -0.95% | +4.70% | +19.51% | +43.00% | 288B | |
| -1.98% | +3.73% | -0.86% | +13.43% | 258B | |
| -0.35% | +4.25% | +46.21% | +50.76% | 234B | |
| -0.75% | +3.32% | +32.53% | +97.21% | 194B | |
| Average | -0.10% | +3.44% | +34.82% | +55.46% | 394.14B | |
| Weighted average by Cap. | +0.13% | +3.83% | +39.18% | +71.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 444M 395M 366M 333M 629M 42.18B 639M 4.4B 1.73B 22.01B 1.67B 1.63B 70.17B | 61.27B 497M 442M 409M 373M 703M 47.17B 714M 4.92B 1.93B 24.62B 1.87B 1.83B 78.47B |
| Net income | 8.66B 70.27M 62.46M 57.89M 52.67M 99.4M 6.67B 101M 696M 273M 3.48B 264M 258M 11.09B | 9.92B 80.47M 71.53M 66.29M 60.32M 114M 7.64B 116M 797M 312M 3.99B 302M 296M 12.7B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/10/26 | BDT 145.80 | +0.62% | 236,050 |
| 14/10/26 | BDT 144.90 | +0.35% | 114,202 |
| 13/10/26 | BDT 144.40 | +0.35% | 197,168 |
| 12/10/26 | BDT 143.90 | +0.49% | 278,825 |
| 11/10/26 | BDT 143.20 | -0.97% | 227,494 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
